Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia, Sara C. Erridge, James Perry, Yong Kil Hong, Kenneth D. Aldape, Benoit Lhermitte, Torsten Pietsch, Danica Grujicic, Joachim P eter Steinbach, Wolfgang Wick, Rafał Tarnawski, Do Hyun Nam, Peter Hau, Astrid Weyerbrock, Martin J B Taphoorn, Chiung Chyi Shen, Nalini Rao, László ThurzoUlrich Herrlinger, Tejpal Gupta, Rolf Dieter Kortmann, Krystyna Adamska, Catherine McBain, Alba A. Brandes, Joerg C hristian Tonn, Oliver Schnell, Thomas Wiegel, Chae Yong Kim, Louis B urt Nabors, David A. Reardon, Martin J. van den Bent, Christine Hicking, Andriy Markivskyy, Martin Picard, Michael Weller, European Organisation for Research and Treatment of Cancer (EORTC), Canadian Brain Tumor Consortium, CENTRIC study team

Research output: Contribution to journal › Article › peer-review

610 Scopus citations

Fingerprint

Dive into the research topics of 'Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences